A Unique Mouse Model for Quantitative Assessment of Biofilm Formation on Surgical Implants in Subcutaneous Abscess
June 6th, 2025
This protocol describes a unique experimental model of implant-related infections that enables the simultaneous incubation of two implants with bacteria under identical conditions within a single mouse. It also allows precise assessment of biofilm formation on implant surfaces using optimized comparative analytical methods, demonstrating advanced techniques for evaluating biomaterials' antimicrobial properties.
Our research aims to develop innovative treatment for implant-related infections. To evaluate novel biomaterials with potential antimicrobial properties, we develop more precious in vivo testing approach. Prior animal models are typically limited to producing a single implant-related infection per animal, which can lead to significant variability in the average outcomes obtained from multiple animals.
Our mouse model allows a direct comparison of the two imprints, subjected to identical infectious conditions within a single animal, hence providing a precious assessment of the antibacterial activity. Our in vivo experimental methodology will accelerate research on potentially antimicrobial biomaterials, contributing to the development of new treatment for implant-related infections in the future. Our experimental approach is replicable with standard equipment and simple procedures in a conventional research setting, hence enhancing comprehension of the mechanisms behind antibacterial activity.
To begin, position the anesthetized mouse on the surgical bed. Fill a 10 milliliter syringe with sterile air and attach a 27 gauge needle to the outlet. Now, gently pinch and elevate the base of the mouse's neck to create space between the subcutaneous tissue and the fascia.
Place the needle into the midline between the mouse's scapulae and inject three milliliters of sterile air subcutaneously to create the air pouch. Then return the mouse to a cage warmed with a thermal pad. Inject three milliliters of sterile air every two days to maintain the cavity's inflation and create a mature pouch.
After anesthetizing the animal, inject it with bupivacaine subcutaneously. Make a three millimeter midline longitudinal incision at the top of the pouch and insert an 18 gauge needle containing the connected wires into the pouch through the hole. Push out the wires using an inner syringe of a 25 gauge spinal needle.
Leaving the tip of the 18 gauge needle inside the pouch, gently remove the inner cylinder and inject Xen36 culture using the syringe carefully. Remove all needles, close the skin using a wound clip and seal with topical skin adhesive. Finally, return the mouse to a cage warmed with a thermal pad for monitoring.
Crystal violet staining showed consistent biofilm formation on both wires without observable differences. Absorbance measurements from the dissolved crystal violet assay showed no statistically significant differences in bacterial load between the two wires. Colony-forming unit counting and quantitative PCR analysis of 16s ribosomal RNA and LuxA genes showed no statistically significant differences in bacterial load between the two wires.
View the full transcript and gain access to thousands of scientific videos
Overview
This study presents a novel mouse model for investigating implant-related infections, allowing for the simultaneous assessment of two implants under identical conditions. This approach enhances the evaluation of antimicrobial properties of biomaterials through precise biofilm analysis.
Key Study Components
Area of Science
- Neuroscience
- Infectious Diseases
- Biomaterials
Background
- Current animal models typically assess only one implant-related infection per subject.
- This limitation can introduce variability in experimental outcomes.
- Understanding biofilm formation is crucial for developing effective antimicrobial treatments.
- Innovative models can streamline the evaluation of new biomaterials.
Purpose of Study
- To create a reliable in vivo model for studying implant-related infections.
- To facilitate direct comparisons of antimicrobial efficacy between two implants.
- To enhance the understanding of the mechanisms behind antibacterial activity.
Methods Used
- Development of a mouse model allowing simultaneous infection of two implants.
- Use of comparative analytical methods for biofilm assessment.
- Application of standard equipment and procedures for replicability.
- Evaluation of novel biomaterials with potential antimicrobial properties.
Main Results
- The model provides consistent and comparable data on implant infections.
- Enhanced assessment of biofilm formation on implant surfaces.
- Demonstrated potential for new treatments targeting implant-related infections.
- Contributes to the understanding of antibacterial mechanisms in biomaterials.
Conclusions
- This innovative model can significantly advance research on antimicrobial biomaterials.
- It offers a more precise evaluation method compared to traditional models.
- The findings may lead to improved treatment strategies for implant-related infections.
Frequently Asked Questions
Executive Industry Relevance
Reliable quantification of biofilm formation on surgical implants is a critical challenge in preclinical biomaterials R&D, directly impacting predictive confidence for antibacterial efficacy. This dual-implant mouse model enables controlled, quantitative comparison of candidate materials under uniform infection conditions, reducing biological variability and supporting robust target validation. The approach strengthens early-stage portfolio decisions by providing reproducible, quantitative data for mechanistic de-risking of novel antibacterial biomaterials.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables direct, quantitative interrogation of antibacterial hypotheses in a controlled in vivo setting.
- Supports functional validation of biomaterial targets by minimizing inter-animal infection heterogeneity.
- Facilitates mechanistic de-risking through standardized biofilm quantification and bacterial load assessment.
- Improves predictive confidence for advancing antibacterial biomaterials in the discovery pipeline.
Screening & Assay Development
- Provides a validated in vivo system for comparative screening of implant materials under identical infectious challenge.
- Delivers reproducible, quantitative outputs via crystal violet staining, CFU counting, and qPCR analysis.
- Enables assay standardization and scalability for downstream compound or material evaluation.
- Supports reliable benchmarking of antibacterial performance for lead identification.
Translational & Preclinical Research
- Aligns preclinical infection models with clinically relevant implant scenarios for translational continuity.
- Enables risk-adjusted advancement of biomaterials with demonstrated in vivo antibacterial activity.
- Provides quantitative endpoints for preclinical go/no-go decisions in antibacterial device development.
- Strengthens the bridge between discovery-stage findings and preclinical validation requirements.
Pipeline & Workflow Integration
This dual-implant mouse model integrates into the discovery-to-preclinical continuum by enabling early, quantitative assessment of antibacterial biomaterials and supporting lead prioritization for further development.
- Discovery Biology: Supports hypothesis testing and biological de-risking by enabling direct comparison of candidate materials in vivo.
- Screening: Provides standardized, reproducible assay outputs for quantitative evaluation of biofilm formation and bacterial load.
- Analytics: Delivers robust measurements via absorbance, CFU, and qPCR to compare experimental conditions objectively.
- Translational Research: Aligns in vivo infection modeling with clinical implant scenarios for improved translational relevance.
- Enterprise Reuse: Offers a replicable, scalable platform for ongoing antibacterial biomaterial evaluation across R&D programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in antibacterial biomaterial validation.
- Operational Value: Enhances reproducibility and standardization of in vivo infection assays.
- Strategic Value: Enables more informed go/no-go decisions and capital-efficient portfolio advancement.
- Portfolio Impact: Supports risk-adjusted prioritization of antibacterial biomaterial candidates for preclinical development.
Implementation Considerations
- Requires expertise in small animal surgery and infection modeling.
- Needs access to standard surgical, microbiological, and molecular analytical infrastructure.
- Demands rigorous cross-team standardization of infection and quantification protocols.
- Adaptable to various implant materials and bacterial strains with protocol optimization.
- Potential limitations include model-specific infection dynamics and scalability to larger systems.
